# Cost-effectiveness of routine COVID-19 adult vaccination programmes in England

Matt J. Keeling<sup>1</sup>, Edward M. Hill<sup>2,3</sup>, Stavros Petrou<sup>4</sup>, Phuong Bich Tran<sup>4</sup>, May Ee Png<sup>4</sup>, Sophie Staniszewska<sup>5</sup>, Corinna Clark<sup>5</sup>, Katie Hassel<sup>6</sup>, Julia Stowe<sup>6</sup>, Nick Andrews<sup>6</sup>

**1** The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, UK.

**2** Civic Health Innovation Labs and Institute of Population Health, University of Liverpool, Liverpool, UK.

**3** NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, UK.

4 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

5 Warwick Medical School, University of Warwick, Coventry, UK.

6 Immunisation Division, UK Health Security Agency, London, UK.

### Abstract

**Background:** In England, and many other countries, immunity to SARS-CoV-2 infection and COVID-19 disease is highly heterogeneous. Immunity has been acquired through natural infection, primary and booster vaccination, while protection has been lost through waning immunity and viral mutation. During the height of the pandemic in England, the main aim was to rapidly protect the population and large supplies of vaccine were pre-purchased, eliminating the need for cost-effective calculations. As we move to an era where for the majority of the population SARS-CoV-2 infections cause relatively mild disease, and vaccine stocks need to be re-purchased, it is important we consider the cost-effectiveness and economic value of COVID-19 vaccination programmes.

1

2

3

4

5

6

7

8

9

Methods: Here using data from 2023 and 2024 in England on COVID-19 hospital admissions, ICU admissions and deaths, coupled with bespoke health economic costs, we consider the willingness to pay threshold for COVID-19 vaccines in different age and risk groups. We partition the population into sixteen 5-year age-groups and three risk groups (no-risk, at-risk and immunosuppressed) and calculate the health savings, in terms of costs and quality adjusted life years (QALYs), per vaccine dose. We adopt three different methodological approaches to estimate the level of vaccine protection leading to five different estimates of efficacy.

**Findings:** Willingness to pay thresholds vary from less than £1 for younger age-groups without any risk factors, to over £100 for older age-groups with comorbidities that place them at risk. This extreme non-linear dependence on age, means that despite the different method of estimating vaccine efficacy, there is considerable qualitative agreement on the willingness to pay threshold, and therefore which ages it is cost-effective to vaccinate. For pre-purchased vaccine, where the only cost is administration ( $\approx$ £10), a twice-yearly universal booster offer to all those aged 70 and over is cost-effective (the benefits 22

perpetuity. It is made available under a CC-BY 4.0 International license .

outweigh the administration costs), while for the at-risk group this could be extended to those over  $^{23}$ 65. When the vaccine cost is included, the cost-effective ages reduce, such that at a total cost of £30  $^{24}$ (for vaccine and administration) universal vaccine is only cost-effective for those over 75; while at £60  $^{25}$ universal vaccine is only cost-effective for those over 80.  $^{26}$ 

Interpretation: The historic offer of COVID-19 vaccination to those 65 and over for the autumn 27 2023 programme and those over 75 for the spring 2023 programme, aligns with our cost-effective 28 threshold for pre-purchased vaccine when the only cost was administration. However, for future pro-29 grammes, when vaccine costs are included, the age-thresholds slowly increase thereby demonstrating 30 the continued importance of protecting the eldest and most vulnerable in the population. 31

32

59

## 1 Introduction

The rapid development of COVID-19 specific vaccines was a major scientific triumph, which had 33 profound implications for the control of a pandemic when population-level immunity to SARS-CoV-2 34 (the causative pathogen of COVID-19) was relatively low. As we move into a scenario in England 35 where the majority of the population have been infected at least once by SARS-CoV-2 [1], and most 36 people have had multiple primary and booster vaccine doses [2, 3], it becomes important to rigorously 37 quantify the impact and cost-effectiveness of future COVID-19 vaccination programmes. Compared to 38 modelling and analysis of COVID-19 vaccination for England in the initial years of the pandemic [4–6], 39 this later problem is confounded by the high variation in immunity within the population to SARS-40 CoV-2 infection and COVID-19 severity. 41

As a consequence, it is no-longer possible to utilise a simply defined efficacy that relates the protection offered by a COVID-19 vaccine to the risks experienced by unvaccinated individuals [7]. The analysis of the potential impact and cost-effectiveness of future COVID-19 vaccination programmes therefore arequires a pragmatic quantitative approach that accounts for this extreme heterogeneity. For example, a cost-effectiveness analysis of the autumn 2023 vaccination programme in the Netherlands used a one-year decision tree-based cost-effectiveness model [8].

To assess the impact and cost-effectiveness of prospective routine COVID-19 vaccination programmes 48 for England, in this study we take the simplifying approach of contrasting individuals who have recently 49 been vaccinated (in the last six months) with those that have not. We use COVID-19 epidemiological 50 data from England for March 2023 to March 2024, that also partitions the population by age and by 51 three risk groups (not at risk, at risk but not immunosuppressed, and immunosuppressed). We present 52 a collection of methodological approaches (each with differing assumptions) to calculate the risk of 53 severe outcomes (hospital admission, ICU admission or death) and the protection offered by COVID-54 19 vaccination. We combine these estimates with bespoke health economic assessments that capture 55 age and risk dependent heterogeneity in hospital cost and QALY (quality adjusted life years) losses 56 following admission or death. This analysis allows us to calculate the willingness to pay threshold, 57 which determines the price at which costs and benefits are equal. 58

# 2 Results

For the purpose of this study, we partition the data into two equal intervals of 26 weeks associated <sup>60</sup> with protection from the spring and autumn 2023 booster campaigns: spring/summer 2023, from <sup>61</sup> week 11 to week 36 of 2023 (roughly mid-March to mid-September); and winter 2023/24, from week <sup>62</sup> 37 of 2023 to week 10 of 2024 (roughly mid-September to mid-March the subsequent year). Given the <sup>63</sup> lack of seasonal structure in the epidemiological data we acknowledge these partitions are somewhat <sup>64</sup> arbitrary; nonetheless, the results are generally insensitive to the precise temporal divisions. <sup>65</sup>

Throughout we stratified the adult population into 16 different five-year age cohorts (a) from 15-19 66 to 90+, and three different risk groups (r): not at risk; at-risk (but not immunosuppressed); and 67 immunosuppressed. The immunosuppressed group accounts for only 1.7% of the English population 68 (peaking at 4.9% of those 80-84 years old), and therefore any results are subject to considerable 69 uncertainty; we hence restrict our attention to the other two risk stratifications but return to the 70 immunosuppressed group in the discussion. 71

For each of the sub-groups we had data for the population size, the number of hospital admissions, 72 severe hospital admissions (for brevity we refer to as ICU admissions) and deaths each week partitioned 73 between those vaccinated in the last six months and those unvaccinated in that same time period 74 (Fig. 1). This data allowed us to calculate the rates (and confidence intervals) of different severe 75 health outcomes for each of the sub-groups. If the uptake of vaccine is assumed to be random within 76 a sub-group, then the ratios between the associated rates defines the realised vaccine efficacy. This 77 realised vaccine efficacy should account for the heterogeneous levels of pre-existing partial immunity in 78 the population, including the impacts of past infection and past vaccination. However, it is important 79 to consider some caveats with these data, chiefly that: the severe outcomes data does not separate 80 infection episodes where COVID-19 was the primary or secondary cause; and that we assume outcomes 81 are random within an age- and risk-group (i.e. there is no correlation between the proportion that get 82 vaccinated, take additional precautions or are more severely affected). In the Discussion we elaborate 83 on the potential implications of these data caveats on our findings. 84

We begin by reviewing the temporal pattern of vaccination and severe outcomes (hospital admissions 85 and deaths), summing across all ages, but differentiating by risk-group and vaccination status (Fig. 1). 86 The number of vaccine doses administered (Fig. 1, top panel) has two clear periods of activity (Spring 87 and Autumn); this contrasts with the weekly hospital admissions (Fig. 1, middle panel) and weekly 88 deaths (Fig. 1, bottom panel), which do not show such clear seasonal patterns. 89

We now describe the statistical analysis of these results using the three methods (providing five distinct 90 efficacy estimates) as described mathematically in the methods section. By combining our estimates for 91 the rates of severe outcomes and the level of vaccine protection with the health economic estimates, we 92 arrive at a willingness to pay threshold for the total cost of the vaccine and administration. We follow 93 the guidelines established by the Joint Committee on Vaccination and Immunisation (JCVI - an expert 94 scientific advisory committee which advises the UK government on vaccination and immunisation 95 matters) and calculate two quantities: a central estimate of the willingness to pay threshold (using 96 the maximum likelihood estimates and valuing one Quality Adjusted Life Year or QALY at £20,000) 97 and the threshold for which 90% of scenarios are cost-effective (using £30,000 per QALY and fully 98 accounting for uncertainty). The final willingness to pay threshold is the minimum of these two values, 99 which for the vaccination programmes considered here is generally the central estimate [12]. 100

### Aggregate approach (Method 1)

The simplest method (Method 1) used the aggregate data from one of the 26-week long time periods 102 of interest (the Methods section provides a detailed mathematical description). In principle, this 103 approach can provide estimates of vaccine efficacy for each age and risk group. However, the results 104 are not necessarily reliable when the uptake is biased. For example, during the Autumn 2023 booster 105 programme everyone 65 years of age and above was eligible; for those under 65 but not in a risk group 106 about 1.5 million doses were administered, often due to them being carers or working in frontline 107 health and social care - such individuals may have greater exposure to infection than others of the 108 same age, which would lead to biases in vaccine efficacy estimates. For this reason, we only applied 109 this first method to age-groups where there was a universal offer of vaccination (75 years and above for 110 Spring 2023; 65 years and above for Autumn 2023 booster). As such, Method 1 generates an efficacy 111

medRxiv preprint doi: https://doi.org/10.1101/2024.11.08.24316972; this version posted November 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .





Fig. 1: COVID-19 vaccination and severe outcomes data from 2023 to 2024 in England. We display per week and per 100,000 individuals: vaccinations administered (top); number of hospital admissions (middle); number of deaths (bottom). The data is partitioned by risk group (no-risk in darker shades and at-risk in lighter shades) and vaccination status (recently vaccinated in blue and not recently vaccinated in red). The time period is divided into two 26-week seasons (Spring 2023 in orange and Winter 2023/24 in blue), which capture the spring 2023 or autumn 2023 booster campaigns and the major epidemic waves. The data come from the Secondary Uses Service [9], the ONS death records [10] and UKHSA's Immunisation Information System [11].

that depends on age, season, and risk-group; although the protection does not decline with time-since 112 vaccination. 113

As an exemplar of the calculations conducted for this method, we consider those not at risk and 114 aged 80-84 during the winter 2023/24 season, and calculate the central estimate of the willingness 115 to pay threshold. There were 412,436 individuals in this age and risk group, of whom an average of 116 335,928 had been vaccinated in the previous six months – leaving 76,508 not recently vaccinated. In 117 the recently vaccinated group there were 186 hospital admissions (a rate of 55.4 per 100,000 over the 118



Fig. 2: Efficacy estimates from the five approaches, for no-risk individuals following the autumn 2023 booster. Throughout we present efficacy estimates for protection against hospital admissions in green (triangle symbol), protection against ICU admissions in purple (inverted triangle) and protection against mortality in red (square). For the aggregate estimate (Estimate 1), where we assumed vaccine efficacy was fixed across a six-month interval, we estimated the efficacy for each 5-year age group that was universally offered the vaccine. We display the 95% prediction intervals (spanning 2.5th and 97.5th percentile), with symbols denoting the mean values. Estimates 2a and 2b show the inferred efficacy distributions with either an assumed or fitted decline. Estimates 3a and 3b are based on values from PHS [13] and UKHSA [14]; the PHS estimates assumed the same efficacy for hospital and ICU admission, while the UKHSA estimates assumed the same efficacy for all severe outcomes. Throughout we show 95th percentiles of the prediction interval (shaded ribbons) as well as the mean value (solid lines); symbols show the mean level of efficacy over a six-month period.

six-month period), while in the not recently vaccinated group there were 128 hospital admissions (a 119 rate of 167.3 per 100,000). Combining these numbers returned a vaccine efficacy of 66.9% against 120 hospital admission.

In addition, those that have been recently vaccinated had a shorter average length of stay in hospital: 122 12.8 days compared to 15.0 days for those not recently vaccinated. The average rates and lengths 123 of stay mean that for every thousand doses of vaccine administered to this age and risk group, 1.12 124 hospital admissions and 18.0 days of hospital stay are prevented. (The 18.0 days saving are comprised 125 of both reduced admissions and shorter stays.) These savings can be combined with the health 126 economic estimates that every admission for this age and risk group is associated with an average 127 0.299 QALY loss, and that each day in hospital costs an average of £1182, to produce a willingness to 128 pay threshold of  $\pounds 27.98$  (=  $[1.12 \times 0.299 \times \pounds 20,000 + 18.0 \times \pounds 1182]/1000$ ) per dose for its protection 129 against hospital admission alone. 130

#### Time since vaccination approach (Method 2)

Our second approach (Estimate 2a) used an assumed decline in protection over time (dropping by 74% 132 over six months), generating a population-level average degree of protection (relative to a recently 133 vaccinated individual) for each week. This again allowed us to estimate the basic rates of severe 134 outcomes and the associated vaccine efficacy, and hence to determine the total amount of protection 135 offered by a vaccine over the six-month period. To overcome the issues of biased vaccination in those 136

perpetuity. It is made available under a CC-BY 4.0 International license .

under 65 year old in the no-risk group (as mentioned above), we extrapolate the vaccine efficacy estimates for all no-risk individuals over 65 to the entire no-risk population. We perform a similar extrapolation for the at-risk population, using the efficacy estimated from at-risk individuals over 65 years of age. As such, Method 2 generates an efficacy that depends on season and risk-group (but not age), where the protection declines with time-since vaccination.

Considering hospital admissions, our central estimate of the vaccinate efficacy (in the no-risk group) <sup>142</sup> was 70.0% immediately after vaccination, with an average vaccine efficacy of 47.0% across a six month <sup>143</sup> period. For 80-84 year olds, this adjusts the previous estimates such that for every thousand doses <sup>144</sup> of vaccine, 0.606 hospital admissions and 10.7 days of hospital stay are prevented. Combining these <sup>145</sup> numbers with the health economic costs generated a willingness to pay threshold of £16.27 per dose <sup>146</sup> for its protection against hospital admission. <sup>147</sup>

As an extension to this approach, Estimate 2b used a maximum likelihood approach to determine the 148 appropriate decline in protection since vaccination for hospitalisation and death outcomes separately, 149 based on the data for those over 65 years of age. These estimates suggest a slower decline in protection 150 than assumed for Estimate 2a, and are comparable with recently estimates from Scottish data [13]. 151 For hospital admissions in the no-risk group, our revised central estimate of vaccine efficacy was 62.8%152 immediately after vaccination, with an average vaccine efficacy of 57.7% across a six month period. 153 These revised protection values, change our central estimates for no-risk 80-84 year olds to preventing 154 0.639 hospital admissions and 11.4 days of hospital stay per thousand doses of vaccine; leading to a 155 willingness to pay threshold of £17.24 per dose for protection against hospital admission. 156

157

176

#### Externally predefined vaccine efficacy approach (Method 3)

Our third and final method used vaccine efficacy estimates derived from alternative data sets. The 158 approach could be used for any set of vaccine efficacy estimates [15]; here we make use of two UK-based 159 estimates: Estimate 3a uses vaccine efficacy and waning of protection from Public Health Scotland 160 (PHS) [13]; Estimate 3b uses efficacy estimates estimates from UKHSA [14]. The PHS estimates 161 come from individuals aged over 65 that were part of the Evaluation and Enhanced Surveillance of 162 COVID-19 (EAVE-II) cohort, and included a surveillance period of September 2023 to July 2024. 163 The UKHSA estimates used a test-negative case-control study design, where positive PCR tests from 164 hospitalised individuals are cases and comparable negative PCR tests are controls; this approach has 165 been used to produce official vaccine estimates for the UK [16, 17]. Our approach utilises a probability 166 distribution for the efficacy which is then scaled in a deterministic manner over time. We use this 167 formulation to capture the uncertainty in the peak level of protection, and the pattern of change over 168 time follows the mean of the PHS or UKHSA estimates. As such, Method 3 generates an efficacy that 169 is the same for all ages, seasons and risk groups although the protection does decline with time-since 170 vaccination. 171

For hospital admissions, the PHS estimates generated a mean vaccine protection across a six month period of 65.3% (Method 3a), while the UKHSA estimates led to 27.1% protection (Method 3b). These vaccine efficacy estimates correspond to willingness to pay thresholds of £18.74 and £8.86 per dose respectively for protection against hospital admission.

### 2.1 Willingness to pay thresholds

Similar calculations can be performed for ICU admissions and deaths, for different age and risk groups 177 and for Spring 2023 and Autumn 2023 boosters; the full calculation also computes the probability 178 distribution associated with the rates and therefore captures the uncertainty in the vaccine protection 179 (see Methods). These statistical results can then be combined with the health economic costs and 180

perpetuity. It is made available under a CC-BY 4.0 International license .

benefits, which also capture uncertainties to generate a total willingness to pay threshold accounting for all the outcomes and following the JCVI guidelines on dealing with uncertainty.

For the spring 2023 and autumn 2023 boosters, and the six-month period of COVID-19 infection, Fig. 3 183 shows the willingness to pay threshold for different ages, two different risk groups and the five different 184 methods of calculating the rate and efficacy distributions. We did not apply Method 1 (aggregated 185 calculation method) to groups with insufficient data or where we believed there was a notable bias 186 between those receiving a booster dose and those that did not (under 65 for the autumn 2023 booster 187 and under 75 for the spring 2023 booster). For each Method, we independently calculated vaccine 188 efficacy values for each booster season (spring 2023, autumn 2023) and for protection against the three 189 forms of severe disease outcome (hospital admission, ICU admission and death). 190

All methods, risk-groups and seasons show the same basic trend: willingness to pay increases dra-191 matically with age, capturing the well-recognised observation that older individuals are more at risk 192 of severe outcomes following COVID-19 infection [6, 18, 19]. The results also highlight the gener-193 ally higher willingness to pay (across all age-groups and methods) for individuals classified as at-risk 194 compared to no-risk, due to the higher chance of more severe outcomes. Finally we observe higher 195 willingness to pay for the autumn 2023 booster compared to the spring 2023 booster, due to the higher 196 number of infections in the associated winter period. We note that the JCVI require both the central 197 estimate (at  $\pounds 20,000$  per QALY) and 90% of uncertainty scenarios (at  $\pounds 30,000$  per QALY) to be cost 198 effective - this translates to the final willingness to pay threshold being the minimum of the most likely 199 value (dot in Fig. 3) and the 80% credible interval (narrower box in Fig. 3). 200

We consider the implications for the willingness to pay threshold for each age-group (Table 1) in 201 terms of who should be offered the vaccine. Given the uncertainty in the seasonality of COVID-19 202 cases (we have yet to experience a single distinct winter wave or even a consistent seasonal pattern) we 203 amalgamate results from the spring 2023 and autumn 2023 boosters, and report the average willingness 204 to pay threshold across both boosters. In addition, it is thought that there is substantially better 205 vaccine uptake from a universal programme rather than one that targets at-risk groups. Therefore, 206 we also report the weighted average which is willingness to pay threshold for a universal programme. 207 We again see the general trends that older age-groups have a higher willingness to pay threshold, such 208 that vaccination is more likely to be cost-effective. 209

210

#### Pre-purchased vaccine

The COVID-19 booster vaccines used during spring and autumn 2023 were pre-purchased during the 211 pandemic; they can therefore be considered to have zero price. The only cost of vaccination is therefore 212 the administration costs, which have generally been between  $\pounds 7.50$  and  $\pounds 10.04$  (although higher values 213 may apply for administration to house-bound individuals). Using this range as our cost, we observe 214 that vaccination of no-risk individuals aged 75 and older is likely to be cost-effective for all methods 215 of determining efficacy, although for Estimate 3b (UKHSA vaccine efficacy [14]) this will be sensitive 216 to the precise costs of administration. We note that even a vaccine with 100% efficacy (not shown) 217 is not cost effective for no-risk individuals under age 65 as the administration costs are greater than 218 the benefits. For at-risk individuals, the age at which vaccination is cost effective reduces to either 60 219 or 65 years of age depending on the method used; while for a universal vaccine the age threshold is 220 either 65 or 70 years old. 221

Taking Method 2 (Estimates 2a and 2b) as our benchmark, we would therefore suggest that the ideal  $^{222}$  strategy for a pre-purchased vaccine would be to offer a universal vaccination to all individuals over  $^{223}$  70, and also to offer vaccination to at-risk individuals over 65. While vaccination of those aged 70-74  $^{224}$  in the no-risk group is not predicted to be cost-effective (willingness to pay is £6-7), the advantages  $^{225}$  in terms of higher uptake in the at-risk group of a universal programme is likely to off-set any costs  $^{226}$ 



Fig. 3: Using data from the spring and autumn 2023 boosters and the 2023/24 winter wave of COVID-19, vaccine threshold prices stratified by age-group, risk-group and modelling approach. We calculate the vaccine threshold price for the two time periods (top row: winter 2023/24; bottom row: spring 2023), 16 age groups (y-axis), three risk groups (panels) and five methodologies (red, dark-blue, light-blue, grey and black). Dots show the most likely value assuming £20,000 per QALY; when assuming £30,000 per QALY the extended bar-and-whisker plots show the 95%, 80% and 50% credible intervals combining all sources of uncertainty. Points that are above or below the axis are shown as triangles. Note that the y-scale is non-linear to better display lower willingness to pay thresholds.

in the no-risk group.

If we consider the spring 2023 and autumn 2023 boosters separately then we find the age thresholds <sup>228</sup> for universal vaccination are 75 and 65 respectively (Tables 3 and 4 in the Supplementary Tables). <sup>229</sup> These estimates come with the benefit of hindsight, such that the scale of the outbreak is known, as <sup>230</sup> is the vaccine efficacy; therefore it is remarkable that these are in agreement with the JCVI advice for <sup>231</sup> individuals not at risk for these booster programmes [20, 21]. <sup>232</sup>

#### Purchased vaccine

In the immediate future, it will become necessary for the UK to purchase vaccines and place vaccination 234 against COVID-19 on a equal cost-benefit assessment as all other vaccines. Which age-groups it is 235 cost-effective to vaccinate will be highly dependent on the price paid for the vaccine, which is currently 236 unknown. To illustrate the patterns, here we consider £25, £50 and £75 as combined costs for the 237 vaccine and administration. 238

At £25 per dose delivered, all Methods broadly agree that universal vaccination of those aged over 75 239 is likely to be cost effective, assuming that losses from vaccinating no-risk individuals aged 75-79 are 240 compensated for by an increased uptake in at-risk individuals in the same age-group. It is uncertain 241 whether vaccination of 70-74 year olds in the at-risk group will be cost-effective with different Methods 242

8

227

producing conflicting results, potentially suggesting a need to refine the co-morbidities that define at-243 risk. 244

At £50 per dose delivered, the age threshold for universal vaccination increases to 80 (Estimates 1 245 and 3a) or 85 (Estimates 2a, 2b and 3b). Only Methods 1 and 3a suggest that vaccinating younger 246 individuals (those aged 75-79) in at-risk groups could be cost-effective. Finally, at £75 per administered 247 dose, it is likely that universal vaccination is only cost-effective for those over 85; although Method 3a 248 suggests universal vaccination is not cost-effective at any age, and only vaccination of at-risk individuals 249 over 90 is cost-effective. 250

#### 2.2Sensitivity

Some of the uncertainties in our epidemiological and health-economic model can be quantified. For 252 example, based on the available data, inferring the rate of hospital admissions produces a detailed 253 distribution of parameter uncertainty (Fig. 2). However, for other elements - such as those associated 254 with the precise scale and timing of future waves, or the degree of protection against future vari-255 ants - the uncertainty cannot be quantified; we cannot determine the probability that the 2024/25256 winter wave will be bigger (or smaller) than the 2023/24 winter wave. For these uncertainties we 257 present an uncertainty analysis, showing the willingness to pay threshold as a function of the unknown 258 quantity. 259

Retaining our focus on universal vaccination, and using Method 2 (Estimates 2a and 2b) throughout, 260 we consider three sensitivities: a shift to the timing of the wave(s); a rescaling of the size of the 261 wave(s); and different levels of vaccine protection (Fig. 4). We also use a combined cost of  $\pounds 25$  per 262 administered dose to illustrate the impact of these uncertainties, but the implication of other costs 263 can be assessed from Fig. 4. 264

Changes to the timing of the waves has the smallest impact on the willingness to pay thresholds (Fig. 4, 265 top-left). Earlier waves consistently reduce the threshold, such that if the waves were 4-7 weeks earlier 266 (depending on the Method) it may no-longer be cost effective to offer universal vaccination to those 267 aged 75-79. There is some evidence that earlier vaccination by around four weeks could increase the 268 benefit of vaccination (assuming the timing of the waves remained the same). 269

The size of the waves of hospital admissions and deaths has a linear impact on the willingness to 270 pay (Fig. 4 top-right). At the £25 cost, very large waves could lead to vaccination of 65-69 year olds 271 being cost effective, although this would require outbreaks more severe than those of Winter 2022-272 23. Similarly, waves that are consistently 15-25% smaller lead to the vaccination of 75-79 year olds 273 no-longer being cost-effective. 274

We consider uncertainty in vaccine efficacy to capture either improvements in vaccine targeting or 275 the risk of evolution of vaccine escape. For the 65-69 age group, it would require a near perfect 276 efficacy for the vaccination of this age-group (at a cost of  $\pounds 25$ ) to be cost effective. Similarly, a large 277 improvement in efficacy is required for universal vaccine of those aged 70-74 to be cost effective at  $\pounds 25$ 278 per administered dose. For older age-groups (for example 80-84 year olds), the efficacy would need to 279 be extremely low to change the cost effectiveness. 280

rges	acy.	d is	
igh 8	effici	shol	ý
thou	the	$_{\mathrm{thre}}$	cerisł
s (al	iing	pay	n ast
age	rmir	s to	th a
r all	dete	gnes	d wi
in fo	s of	villin	arke
give	thod	the v	re m
s are	e me	lere 1	Т) а
lolds	e fiv	s wh	QAL
hresl	or th	thod	per
E .	nd fc	l me	,000
sters	nt aı	s and	f30
boo	yme	dnoj	ss at
)23	leplc	isk-g	vene
n 2(	ine e	es, ri	fecti
tum	vacc	. Ag	st-ef
/Au	ersal	ated	of cc
ring,	unive	indic	ance
$\mathbf{S}\mathbf{p}_{\mathbf{I}}$	and	are	δ chε
ined	risk	ı £1	1 90 <sup>0</sup>
dmo	, at-	$_{\mathrm{thar}}$	e is 8
e cc	-risk	less	there
r th	r no	alues	chat
ls fo	r), fo	nd vi	on (1
hold	licity	id, aı	nditi
hres	simp	unod	y co
t]	for	rest ]	taint
o pa	ated	near	ncer
ss t	gam	the	N IN
ngne	amal	ed to	e JC
Villin	een	pund	y th
×	we b	re rc	ted b
le 1	9 ha	les a	ermir
$\mathbf{Iab}$	15-3	Valı	let€

			Jnivers	al				<b>No Risk</b>	4				At Risk		
Age	E1	E2a	E2b	E3a	E3b	E1	E2a	E2b	E3a	E3b	E1	E2a	E2b	E3a	
15 - 39	•	< £1	< £1	< £1	< £1	I	< £1	< £1	< £1	< £1	1	$\leq \text{£2}^{\star}$	$\leq \text{£2}^{\star}$	<ul><li>∠</li></ul>	$ \vee $
40-44	•	£1	£1	£1	< £1	ı	< £1	<£1 *	< £1	< £1	ı	£3	f2	$f_{2}$	
45-49	ı	£1	£1	f2	£1	I	£1 *	< £1	£1	$< \pounds 1$	ı	£3	f3	f6	4
50-54	ı	f2	f2	f3	$\pounds 2$	I	£1	£1	£1	£1	$< \pounds 1$	f6	$\mathfrak{L}\mathfrak{Z}$	$\pounds 10$	сң
55-59	ı	£3	£3	£3	$\pounds 2$	I	£1	£1	£1	£1	< £1	£8	£7	$\pounds 13$	CH3
60-64	•	f5	£4	£7	£4	ı	£2	£2	f2	£1	£2 *	$\pounds 10$	£8	$\pounds 16$	4
62-69	£8 *	£11	£9	$\pounds 16$	£8	£4 *	£4	$\mathfrak{L3}$	£4	f2	£14 *	$\pounds 19$	$\pounds 16$	$\pounds 30$	3
70-74	£17	$\pounds16$	$\pounds 13$	$\pounds 25$	$\pounds 12$	£8 *	£7	$\mathfrak{E6}$	$f_{2}$	$\mathfrak{L}4$	$\pounds 25$	$\pounds24$	$\pounds 20$	$\pounds41$	ά
75-79	$\pounds 51$	f33	$\pounds 30$	$\pounds 57$	$\pounds 24$	$\pounds 31$	£17	£17	$\pounds 19$	£8	f63	$\pounds44$	f38	£81	ಷ
80-84	$\pounds 59$	£46	£41	£89	f35	$\pounds 37$	£27	$\pounds 27$	£31	$\pounds 13$	f67	f53	$\pounds 46$	£112	£4
85-89	£103	£86	$\pounds75$	$\pounds 160$	$\pounds 64$	$\pounds72$	£58	f60	£71	f30	£111	f93	£80	£183	57 12
+06	£85	f89	£77	£188	£72	- - -	£64	f.63	£77	£36	f.103	£94	$f_{80}$	f.210	с <del>н</del>



Fig. 4: Sensitivity of the willingness to pay threshold for universal vaccination to the timing of the epidemic wave, the magnitude of the epidemic waves and the efficacy of the vaccine. For a shift in the timing of waves or waves of different sizes (top row), we consider how the threshold calculated by Estimates 2a (solid line) and 2b (dashed line) for older age-groups vary. When considering the size of the waves, the Spring 2023, Winter 2023-24 and Winter 2022-23 are shown for comparison. For vaccine efficacy, we extrapolate the willingness to pay thresholds from Estimate 2a and consider protection against hospital admissions and mortality separately (bottom row). We consider four age-groups (65-69 to 80-84) and show the contours where the willingness to pay threshold is equal to  $\pounds 7.50$ - $\pounds 10.00$  (grey shaded region),  $\pounds 25$ ,  $\pounds 50$  and  $\pounds 75$ ; we also show the approximate efficacy estimates for the five Methods, weighted so that they apply to universal vaccination over combined spring 2023 and autumn 2023 boosters.

perpetuity. It is made available under a CC-BY 4.0 International license .

### 3 Discussion

Here we have quantified the protection offered by recent COVID-19 booster vaccination by using 282 national data sets on COVID-19 associated hospital admissions, ICU admissions and deaths in England 283 linked to individual vaccination records. We used three different approaches leading to five methods 284 to infer the underlying risk of severe outcomes in different age and risk groups (no-risk, at-risk or 285 immunosuppressed, as defined in the Green book chapter 14a [22]) dependent on vaccination status. 286 We combined these inferred risks with bespoke health economic parameters for COVID-19 on hospital 287 costs and QALY losses to define willingness to pay thresholds according to JCVI guidelines. As 288 such, the willingness to pay threshold defines the maximal combined cost of a vaccine dose plus the 289 administration, such that vaccination would be cost effective; the JCVI guidelines ensure that both 290 the most likely scenario and uncertainty are taken into account in this evaluation. 291

In practice the willingness to pay threshold is used to translate the realised total vaccination cost 292 (vaccine plus administrative costs) into a set of age and risk groups who it should be cost effective 293 to vaccinate. For COVID-19, given the increasing vulnerability with age, this equates to a lower age 294 threshold in each risk group, with everyone older being eligible for vaccination. Table 2 shows this 295 lower age threshold for a range of costs and for universal vaccination and at-risk groups; based on the 296 assumption the universal vaccination has the benefit of increased uptake in the at-risk population). 297 This analysis assumes that the same threshold is applied to both spring and autumn boosters, given 298 the absence of a clear seasonal pattern in COVID-19 cases and outcomes to date. For each cost we 299 show the lowest and highest estimated age threshold together with the associated models. Despite the 300 very different assumptions underpinning the five methods, there is a remarkable level of agreement, in 301 part due to the extreme increase in risk with increasing age. We find that Estimate 3a (PHS estimates) 302 is always associated with the lowest age estimates, while Estimate 3b (UKHSA efficacy estimates) is 303 always associated with the highest estimates - providing bounds on who should be considered for 304 cost-effective vaccination. 305

Table 2: The lower age threshold for cost-effective vaccination using the imputed willingness to pay values. For each combined cost of vaccine and administration, we give the minimum and maximum calculated age thresholds above which vaccination in cost effective, together with the estimates that generate these thresholds.

	Universal Vaccination	At-Risk Vaccination
	threshold age min - max in years	threshold age min - max in years
Total Cost	(associated estimates)	(associated estimates)
£10	65(E2a,E3a) - 70(E1,E2b,E3b)	55(E3a) - 65(E1,E2a,E2b,E3b)
£15	65(E3a) - 75(E2b,E3b)	60(E3a) - 70(E1,E3b)
£20	70(E3a) - 75(E1,E2a,E2b,E3b)	65(E3a) - 75(E2b,E3b)
£25	70(E3a) - 80(E3b)	65(E3a) - 75(E2a,E2b,E3b)
£30	75(E1,E2a,E3a) - 80(E2b,E3b)	65(E3a) - 75(E1,E2a,E2b,E3b)
£35	75(E1,E3a) - 85(E3b)	70(E3a) - 80(E3b)
£40	75(E1,E3a) - 85(E3b)	70(E3a) - 80(E2b,E3b)
£45	75(E1,E3a) - 85(E2b,E3b)	75(E1,E3a) - 85(E3b)
£50	75(E1,E3a) - 85(E2a,E2b,E3b)	75(E1,E3a) - 85(E2b,E3b)
$\pounds 55$	75(E3a) - 85(E2a,E2b,E3b)	75(E1,E3a) - 85(E2a,E2b,E3b)
£60	80(E3a) - 85(E1,E2a,E2b,E3b)	75(E1,E3a) - 85(E2a,E2b,E3b)
£65	80(E3a) - 90(E3b)	75(E3a) - 85(E2a,E2b,E3b)
£70	80(E3a) - 90(E3b)	75(E3a) - 85(E1,E2a,E2b,E3b)
£75	80(E3a) - 95(E3b)	75(E3a) - 90(E3b)

perpetuity. It is made available under a CC-BY 4.0 International license .

For low total costs (generally associated with the assumption that the vaccine is pre-purchased and 306 therefore zero cost), we find that universal vaccination is cost-effective for those aged over either 65 307 or 70 depending on the methodology employed; however the majority of the models agree that for 308 those in the at-risk group vaccination should be offered to those 65 and over. For slightly higher 309 combined costs, for example at £25, most methods (Estimates 1, 2a and 2b) agree that the universal 310 threshold should be those over age 75, and this is also the most preferred age threshold for the at-risk 311 group. For much higher costs, for example at  $\pounds 50-60$ , the majority of the models suggest that universal 312 vaccination should only be offered to those over the age of 85, with weak or no support for vaccination 313 of younger at-risk individuals. 314

Those who are immunosuppressed form a small but highly vulnerable part of the population. Due to the small size of this risk group, and the heterogeneity within it, results from all estimations of efficacy are extremely noisy. However, as a general rule, vaccination of all immunosuppressed individuals over age 35 (or age 45-55 depending of the method) is cost effective at £10 (or £25) per administered dose. Results for younger age-groups, which are only a small proportion of the immunosuppressed population are highly variable, suggesting that uniform vaccination of the entire immunosuppressed population may be the most precautionary option.

There are some limitations of our analysis, primarily associated with the properties of the data. The 322 partition of the population into just risk groups (no-risk, at-risk but not immunosuppressed and 323 immunosuppressed) is somewhat simplistic. It is likely, that a finer partitioning of the risk groups 324 could increase the willingness to pay threshold for some risk groups, although this has to be weighed 325 against the practicalities of more complex criteria. For example, recently diagnosed haematological 326 malignancy or severely reduced kidney function would both place an individual in the at-risk (but 327 not immunosuppressed) group; these conditions have been observed to have a substantially greater 328 impact on the risk of severe outcomes than chronic heart disease which also places an individual in 329 the at-risk group [22, 23]. There are also implications if those accepting vaccination are a biased 330 sample of the individual sub-groups (for example, those who perceive themselves at greatest risk may 331 be more likely to be vaccinated). Such biases would reduce the estimated efficacy from Methods 1 332 and 2. Another potential issue with the data is whether individuals are hospitalised 'with COVID' 333 (that is, they have COVID-19 infection at the time of admission but it is not the cause of admission) 334 or 'for COVID' (that is, COVID-19 infection is the primary cause of their admission). Our selection 335 criteria for admissions has been designed to minimise the numbers where COVID-19 is not a major 336 contributing factor; inclusion of individuals 'with-COVID' will lead to over-estimates the willingness 337 to pay threshold. 338

The static approach we have adopted here provides a worst case scenario as it does not include the 339 indirect protection offered by vaccination. For example, vaccination of 50-54 year olds only accounts 340 for their direct protection against severe COVID-19 disease, and does not account for the associated 341 reduction in the force of infection experienced by more vulnerable individuals, nor any societal impact 342 due to their illness. However, a dynamic approach where SARS-CoV-2 infection is modelled mecha-343 nistically is impractical due to the extreme heterogeneity in history of infection and vaccination. This 344 is exemplified by those studies that have used dynamic SARS-CoV-2 infection transmission models to 345 perform cost-effectiveness analyses of 2023 COVID-19 booster vaccination programmes [24, 25], where 346 heterogeneity is only dependent on vaccine history not infection history. 347

Furthermore, many unquantifiable uncertainties could influence these findings. We have explored <sup>348</sup> the timing and size of waves (Fig. 4), but cannot associate a probability with any pattern of future <sup>349</sup> outbreaks. These results have shown that while both timing and scale of the epidemic wave(s) have <sup>350</sup> an effect on the vaccine threshold price (with scaling having the largest influence) both are relatively <sup>351</sup> small compared to the impact of age, at most changing eligibility by one 5-year age group for the scale <sup>352</sup>

perpetuity. It is made available under a CC-BY 4.0 International license .

of waves recently experienced. More concerning is the potential impact of novel variants. A novel <sup>353</sup> variant with greater severity or which overcame population-level immunity would likely generate far <sup>354</sup> larger waves of severe cases and therefore merit an expansion of the vaccine programme. Similarly, <sup>355</sup> a new variant with sufficient vaccine escape - such that the level or duration of protection induced <sup>356</sup> by prior COVID-19 vaccination was reduced - may require a re-evaluation of the programme, either <sup>357</sup> reducing its range due to the lower impact per dose, or increasing its range to help combat overall <sup>358</sup> levels of infection and hence protect the most vulnerable. <sup>359</sup>

Vaccination against COVID-19 therefore remains an important public health tool for protecting the elderly and most vulnerable in our society. However, wide spread partial immunity in the population, the lower risks of severe illness currently observed, and the need for vaccines to be cost-effective means that offers of population-wide vaccination for all ages are no longer affordable. Instead we need to carefully balance the vaccine costs against the health saving and health benefits; the precise age threshold will depend on the price paid for the vaccine, but only universal programmes that target those above 70 years old are likely to be cost effective. 360

perpetuity. It is made available under a CC-BY 4.0 International license .

## 4 Methods

Here we provide details on the data used throughout this work (Section 4.1), on the different modelling <sup>368</sup> approaches to infer the health episode outcome rates which are dependent on age, risk and vaccination <sup>369</sup> status (Section 4.2), and the health economic data and assumption used to make cost-effectiveness <sup>370</sup> assessments (Section 4.3). When taken together these generate the willingness to pay thresholds for <sup>371</sup> different target groups being included in a routine COVID-19 vaccination programme for England <sup>372</sup> (Section 4.3). <sup>373</sup>

### 4.1 Data on admissions and deaths by age, risk and vaccination status

Our aim was to generate data on the number of individuals each week that were admitted to hospital, admitted to ICU (a term we use for brevity to refer to severe hospitalisation cases) or died with COVID-19. These data are further separated by age (five-year age bins from 15-19 to 90+), risk group (no-risk, at-risk or immunosuppressed, as defined by the Green Book Chapter 14b [22]) and by vaccination status (booster within the last six months or not). This involves the linkage of two data sets on health outcomes (admissions provided by the Secondary Uses Service [9] and deaths provided by the ONS [10]) to individual records on vaccine uptake and demographic status.

The Secondary Uses Service [9] is a database of timely completed hospital admissions, including ICU 382 attendance, for all NHS hospitals in England. To determine COVID-19 related hospitalisations for 383 age 15+ we merged COVID-19 testing data with respiratory coded discharge data obtained from the 384 Secondary User Service. The respiratory discharge ICD-10 codes used were: J04<sup>\*</sup> Acute laryngitis 385 and tracheitis; J09\* Influenza due to identified avian influenza virus; J10\* Influenza with pneumonia, 386 other influenza virus identified; J11\* Influenza with pneumonia, virus not identified; J12\* Viral pneu-387 monia, not elsewhere classified; J13\* Pneumonia due to Streptococcus pneumoniae; J14\* Pneumonia 388 due to Haemophilus influenzae; J15\* Bacterial pneumonia, not elsewhere classified; J16\* Pneumo-389 nia due to other infectious organisms, not elsewhere classified; J17\* Pneumonia in diseases classified 390 elsewhere; J18\* Pneumonia, organism unspecified; J20\* Acute bronchitis; J21\* Acute bronchiolitis; 391 J22\* Unspecified acute lower respiratory infection; J80\* Adult respiratory distress syndrome; U071\* 392 COVID-19, virus identified; U072\* COVID-19, Virus not identified; U04\* Severe acute respiratory 393 syndrome (SARS). 394

We then identified a COVID-19 related hospital admission either by a hospitalisation (with a respiratory coded discharge) that had a COVID-19 positive test (PCR or lateral flow) within the period two days prior to the day after the date of admission, or a discharge where the primary ICD-10 discharge diagnosis was COVID-19.

ICU admissions (corresponding to severe hospitalisation admissions) were those with NHS Office of <sup>399</sup> Population Censuses and Surveys (OPCS) codes for oxygen/ventilation — E85\* Ventilation support, <sup>400</sup> E89\* Other respiratory support, X58\* Artificial support for body system, X52\* Oxygen therapy — or <sup>401</sup> Main Specialty/Treatment Function classification associated with an ICU admission (Main Specialty <sup>402</sup> Code: 192 Critical Care Medicine; Treatment Function Code - reporting the specialised service within <sup>403</sup> which the patient was treated: 192 Critical Care Medicine or 242 Paediatric Intensive Care). We <sup>404</sup> collectively refer to these severe hospitalisation admissions as ICU admissions. <sup>405</sup>

We collapsed hospitalisations in the same individuals into 'spells' where there was more than one admission recorded on the same day or where spells overlapped (based on admission and discharge). We combined spells within individuals if two spells started within 15 days of one another. In these combined spells we counted information on severity if it occurred in any of the collapsed admissions.

Formal ONS deaths were identified with COVID-19 mentioned on the death certificate [10].

367

374

perpetuity. It is made available under a CC-BY 4.0 International license .

Both set of individuals (admissions and deaths) were then linked to UKHSA's national COVID-19<sup>411</sup> vaccine register, the Immunisation Information System (IIS) [11], that holds COVID-19 vaccine dates, <sup>412</sup> COVID-19 vaccine eligible risk group status [26] and demographic information for all individuals in <sup>413</sup> England. Linkage was performed by matching NHS numbers; matching was perfect for admissions, <sup>414</sup> but failed for around 6% of deaths. The age of these unmatched deaths is known, but vaccination and <sup>415</sup> risk status is randomly assigned based on those with known status. <sup>416</sup>

Vaccine coverage data for each week was also derived from the IIS using age on 31st August of each 417 year. 418

### 4.2 Mathematical outline of the modelling approaches

We used three differing modelling methodology leading to five different estimates of the protection 420 offered by COVID-19 vaccination. The first method we call the 'aggregate approach', the second 421 method we call the 'time since vaccination approach' and the third method we call the 'externally 422 predefined vaccine efficacy approach'. 423

We base each approach on having a set of weekly observations of a particular public health outcome (admission to hospital, admission to ICU or death due to COVID-19), summed across all ages and risk groups; we label this quantity  $Y_w$ . We also defined the normalised rate of weekly observations:

$$\widehat{Y}_w = \frac{1}{\sum_{\omega} Y_{\omega}} Y_w$$

For all that follows we consider a particular age and risk class and a particular observation of a public health outcome; when performing our numerical calculations we need to keep track of these three dimensions, but here for notational brevity we outline how the calculations are performed for a single risk-group, age-class and set of observations. We denote the size of the population as N, the number of individuals vaccinated within the last six months as  $V_w$  (given the current week being w) and the number vaccinated exactly W weeks ago (that is vaccinated in week w - W) as  $V_w^W$ . It should be noted that  $\sum_{W < 6 \text{ months}} V_w^W = V_w$ . For simplicity of notation we define those individuals that have not been vaccinated in the last six months by  $U_w = N - V_w$ .

For a given observation, we assumed the number observed in a given week (w) for a particular public health outcome for those not vaccinated in the last six months was  $y_w^U$ . Similarly, we assumed the number observed in a given week for a particular public health outcome for those that had been vaccinated in the last six months was  $y_w^V$ .

#### Method 1: Aggregate approach

Our simplest calculation was to consider the rate s (or r) that a random person in the vaccinated (or <sup>437</sup> unvaccinated) group enters our observation class, assuming a Poisson distribution. The probability <sup>438</sup> distribution of a particular rate is proportional to the likelihood: <sup>439</sup>

$$P_U(r) \propto \operatorname{Poisson}\left(\sum_w y_w^U | r \overline{U}_w\right) \pi(r)$$

$$P_V(s) \propto \operatorname{Poisson}\left(\sum_w y_w^V | s \overline{V}_w\right) \pi(s)$$
(1)

with the proportionality constant defined such that the distribution integrates to one. Here  $\overline{U_w}$  and  $\overline{V_w}$  refer to the average number of unvaccinated and vaccinated individuals during the time period, 441 and  $\pi$  is the weakly informative prior probability distribution for the per capita rate of observation 442  $(\pi(r) = exp(-r))$ .

436

perpetuity. It is made available under a CC-BY 4.0 International license .

Given our assumption that the per capita risks for vaccinated and unvaccinated individuals are independent, the joint distribution is given by the product:

$$\overline{P}_J(r,s) = P_U(r) P_V(s) \tag{2}$$

The probability distribution for the vaccine efficacy  $\rho = 1 - s/r$  can then be calculated as:

$$P_{\text{eff}}(\rho) = \int_0^\infty r \overline{P}_J(r, r(1-\rho)) dr$$
(3)

where the r term in the integral is the natural scaling, and ensures that the probability to integrate 447 to one. This approach effectively treats the entire outbreak as a single observation. 448

449

450

446

#### Method 2: Time since vaccination approach

Method 2 requires two combined elements to realise the risks and efficacy distributions: firstly, a <sup>451</sup> method to determine the efficacy assuming that the level of protection wanes after vaccination; and <sup>452</sup> secondly, a method to include the estimated efficacy into the rate estimation approach. This two-step <sup>453</sup> process is needed as we combine the estimated efficacy from older age-groups (which we believe is <sup>454</sup> subject to fewer biases) and use this distribution for all ages. <sup>455</sup>

To acknowledge that the level of protection from the vaccine wanes over time, we define the relative level of protection from the vaccine after W weeks  $X^W$ , which peaks at one and is assumed to decay substantially by the time when W reaches six months. For Estimate 2a, we assume that  $X^W = \exp(-W^2/500)$  which produces a decline similar to that estimated against the initial Omicron BA.1 wave [27]. At any time, we can then define the aggregate level of protection across the entire population  $x_w$  in week w as:

$$x_w = \sum_W X^W \frac{V_w^W}{V_w}$$

where  $V_w^W$  is the number of individuals vaccinated W weeks ago, and  $V_w$  the number vaccinated within the last six months. Given that the level of protection for vaccinated individuals depends on both s(the rate when the vaccine offers maximal protection) and r (the rate when the vaccine offers least protection, assumed to be after six months), it is practical to consider the joint distribution: 459

$$P_J(r,s) \propto \prod_w \text{Poisson}\left(y_w^U | rU_w \widehat{Y}_w\right) \text{Poisson}\left(y_w^V | (r(1-x_w)+sx_w)V_w \widehat{Y}_w\right) \pi(r)\pi(s)$$
(4)

Here, the rate of observation for vaccinated individuals is a weighted combination of r and s depending on the population level amount of protection at any given time,  $x_w$ . The probability distribution of efficacy can again be defined from this joint distribution:

$$P_{\text{eff}}(\rho) = \int_0^\infty r P_J(r, r(1-\rho)) dr$$

As an extension to this approach, Estimate 2b allowed the decline in protection to be estimated. We define  $X^W = \exp(-W^2/(2\sigma^2))$ , and set  $\sigma$  to maximise Eq. (4) across all age-groups but independently for each public health outcome. 462

For Method 2 (and hence Estimates 2a and 2b) we combine (by taking the product) the estimated 463 efficacies,  $P_{\text{eff}}(\rho)$ , for multiple older age-groups, and once normalised, treat this combined probability ( $\pi_{\text{Eff}}(\rho)$ ) as the efficacy distribution across all age-groups. The ages chosen to be aggregated, and hence 465

perpetuity. It is made available under a CC-BY 4.0 International license .

used as a sample for the entire population, correspond to those older age-groups where vaccination was universally offered irrespective of risk status. To calculate the impact of vaccination then requires an approach that can determine the rates consistent with the assumed efficacy distribution  $\pi_{\text{Eff}}(\rho)$ .

The joint distribution of the rates r and the efficacy  $\rho$  can then be expressed as:

$$Q_J(r,\rho) = \pi_{\text{Eff}}(\rho) \frac{P_J(r,s=r(1-\rho))}{\int P_J(r,s) \, ds}$$
(5)

where  $P_J$  is defined as in Eq. (4). This allows us to calculate the appropriate joint distribution on the two rates: 470

$$\overline{P}_J(r,s) = r Q_J(r,1-s/r) \tag{6}$$

In essence this methodology ensures that the rates for the two groups (vaccinated and unvaccinated) 472 are consistent with both the observations for both classes and the assumed efficacy distribution. 473

However, there are younger individuals in the no-risk group who were vaccinated, and therefore do not represent the average population of that age. (There are reasons why these individuals might have been vaccinated including: being pregnant; working in frontline NHS and social care, or care homes; or being at-risk but incorrectly classified in the data). In such cases it is prudent to exclude these individuals from our analysis, in which case:

$$Q_J(r,\rho) = \pi_{\rm Eff}(\rho) P_U(r)$$

where  $P_U$  is taken from Eq. (1), and then Eq. (6) still holds.

#### Method 3: Externally predefined vaccine efficacy approach

For Method 3 (generating Estimates 3a and 3b) the efficacy has been estimated in advance, which requires a slight adjustment to our previous approach. Usually, the available estimates may be of the efficacy distribution at different times since vaccination (e.g.  $\Pi_{\text{Eff}}(\rho, W)$  in week W). Here, in keeping with our previous approaches, we approximate this externally derived distribution with a single distribution ( $\pi_{\text{Eff}}(\rho)$ ) coupled with a deterministic scaling in protection  $X^W$  which is also informed by the external data. Using  $\pi_{\text{Eff}}$  and  $X^W$  based on the external source, we can again return to Eqs. (5) and (6) to inform about the rates.

#### 4.3 Evaluating vaccine programme cost-effectiveness

For the respective modelling approaches outlined above, the health outcome rates and vaccine efficacy 484 estimates, we detail the cost-effectiveness assessments. For each of the different target groups being 485 included in a routine COVID-19 vaccination programme for England, this generated a willingness to 486 pay for each administered vaccine (the combined cost of administration and purchase of the vaccine). 487 We first explain the health economic calculations that determined the price point that a vaccine dose 488 would be deemed cost effective. We then overview the use of the health economic parameters within 489 the cost effectiveness assessment. 490

#### Health economic model calculations

Following from the joint probability density calculations outlined above, we computed the probability density for the health economic benefit  $(B = rCost_U - sCost_V)$  of a single dose of vaccine as:

$$P_{\text{benefit}}(B) = \int_0^\infty \frac{1}{CostV} P_J\left(r, \frac{rCost_U - B}{CostV}\right) dr \tag{7}$$

474

475

469

483

It is made available under a CC-BY 4.0 International license.

For vaccinated and unvaccinated groups respectively,  $Cost_V$  and  $Cost_U$  represent the total cost associated with whichever severe outcome is being considered (hospital admission, ICU admission or death) and include both direct treatment costs and the value placed on QALY losses. In this formulation, the joint distribution  $(P_J)$  can be as defined by Eq. (2) (for Method 1) or Eq. (6) (for Methods 2 and 3).

Following JCVI guidelines we considered two quantities [12]. First, using the mean costs and benefits, and assuming one QALY (Quality Adjusted Life Year) is valued at £20,000; we calculated the benefit per vaccine dose at the maximum likelihood values for the rate a random person in the unvaccinated group has the severe outcome under consideration  $(r^*)$  and the rate a random person in the vaccinated group has the severe outcome  $(s^*)$ :

Benefit<sub>MLE</sub> =  $r^* Cost_U - s^* Cost_V$  where  $P_J(r^*, s^*)$  is the global maximum

Second, using  $\pounds 30,000$  per QALY and accounting for variability in cost and rate parameters, we calculated the 10th percentile of the distribution: 505

Benefit<sub>10%</sub> = B such that 
$$\int_0^B P_{\text{benefit}}(b) \, db = 0.1$$

A vaccine is then deemed cost effective if the cost per dose including administration is less than both the calculated benefits:

Vaccine price + Admisistration price <  $min(Benefit_{MLE}, Benefit_{10\%})$  = Willingness to pay threshold.

#### Parameters of the health economic model

The health economic calculations required monetary costs and a measure of disease severity (captured <sup>507</sup> through the loss of Quality-adjusted life years, QALYs) associated with each level of disease outcome. <sup>508</sup> For infection episodes resulting in hospitalisation and ICU admission, we derived estimates from the <sup>509</sup> PANORAMIC trial (Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 <sup>510</sup> in the Community) [28] (Table 5 in the Supplementary Tables). <sup>511</sup>

**PANORAMIC trial.** The purpose of the PANORAMIC trial was to find out in which people new 512 antiviral treatments for COVID-19 in the community could reduce the need for hospital admission 513 and improve health outcomes. Participants enrolled in the PANORAMIC trial had tested positive for 514 SARS-CoV-2 infection, had ongoing symptoms consistent with COVID-19, had not been previously 515 hospitalised due to COVID-19 (a criteria resulting from the trial focus being on community-based 516 treatment) and were either aged 50 years or older, or were aged between 18 to 49 years old and 517 considered clinically vulnerable. Although some of these criteria may produce a bias in terms of rates 518 of hospital admission, given we only use to PANORAMIC trial to estimate the cost of hospital episodes 519 any bias should be minimal. 520

We further limited the eligible participants for the calculation of our health economic parameter estimated. This step comprised limiting to participants from England (85.3% of the trial population), participants who had received at least one dose of vaccination, and participants who were treated with either molnupiravir or usual care.

We grouped participants into the following health states based on the reporting of any pre-existing medical conditions: Immunocompromised - participant-reported having a weakened immune system; 526 Not immunocompromised but high risk - participant-reported lung disease, heart disease, diabetes, 527 or obesity; Not at risk - participant reported not having any of the aforementioned medical conditions. 528

perpetuity. It is made available under a CC-BY 4.0 International license.

Cost calculations: Hospital and ICU admissions. In our analysis we assumed the raw hospitali-530 sation (or ICU costs) for vaccinated and unvaccinated individuals to be equal, with only the associated 531 length of stay  $(LoS_U \text{ and } LoS_V)$  varying. 532

Hospital admission costs were a function of the age of the individual and their risk status:

$$Cost_X(a, r, hospital) = C_h(a, r) \times LoS_X(a, r) + QALY \times Q_h(a, r)$$

where  $X \in \{U, V\}$  and QALY is the monetary value associated with one QALY loss (either £20,000) 534 for our central estimate or  $\pounds 30,000$  when considering uncertainty). We had age and risk dependent 535 per day cost  $C_h$  and loss of QALYS  $Q_h$  estimated from the PANORAMIC study (Fig. 5, left-hand 536 column). 537

For costs associated with ICU admission we made a similar calculation:

$$Cost_X(a, r, ICU) = C_I(a, r) \times LoS_X(a, r) + QALY \times Q_I(a, r)$$

with per day cost  $C_I$  and loss of QALYS  $Q_I$  again being age and risk dependent (Fig. 5, right-hand 539 column). 540

We took hospital admission unit costs from the NHS 2022/23 National Cost Collection Data Publi-541 cation [29], then attached the appropriate Healthcare Resource Group (HRG) code to each patient to 542 get their hospitalisation (or ICU) cost per episode. The cost of each patient was then divided by the 543 number of days in the hospital (or ICU) to get the hospitalisation (or ICU) cost per day. We computed 544 costs over six months, adjusted by trial allocation group and sex. We analysed adjusted values using 545 a generalised linear model with log-link. 546

We valued QALYs using EQ-5D-5L and UK utility values, derived using the approach recommended 547 by NICE [30]. This approach applies a validated mapping function onto the UK EQ-5D-3L tariff 548 set that has been developed by the NICE Decision Support Unit [30]. We adjusted QALYs lost by 549 trial allocation group, sex and baseline EQ-5D-3L utility score. We analysed adjusted QALYs using 550 beta-regression. 551

For hospital and ICU admissions we factored in the uncertainty in the monetary cost and QALY-552 loss estimates. The uncertainty in QALY losses was especially substantial for those admitted to ICU 553 (Fig. 5). 554

**Cost calculations: Deaths.** For infection episodes resulting in mortality (Fig. 5, lower panel), we 555 assumed no monetary costs and assumed that QALY losses  $(Q_D)$  depended on both age and risk 556 group: 557

$$Cost_X(a, death) = QALY \times Q_D(a, r)$$

The quality-adjusted life-year losses associated with COVID-19 deaths  $(Q_D(a, r))$  were sourced from 558 the literature. These accounted for QALY losses at various ages and adjusted for the presence of co-559 morbidities that influence both life-expectancy and health-related quality of life [31]. The standard life 560 expectancy estimation approach, which focuses on conditional life expectancy upon reaching a specific 561 age, were modified to incorporate: (i) the impact of comorbidities on life expectancy using the stan-562 dardized mortality ratio (SMR); (ii) the effect of pre-existing comorbidities on health-related quality 563 of life (qCM) to estimate QALYs over time; and (iii) discounting ( $\varepsilon = 0.035$  throughout) [31]. 564

The following parameters were assumed for different risk groups: for the immunocompromised group, 565 defined as participants reporting a weakened immune system (SMR = 2; qCM = 0.8); for the not 566 immunocompromised but high risk group—e.g., those reporting lung disease, heart disease, diabetes, 567 or obesity (SMR = 1.5; qCM = 0.9); and for the low-risk group—participants without the mentioned 568 medical conditions (SMR = 1; qCM = 1). Since these are arbitrary thresholds, we reviewed relevant 569

538

literature to check their appropriateness and found that our assumptions generally aligned with estab-570 lished findings [32–34]. However, it is important to note that multimorbidity and immunosuppression 571 exist on a spectrum concerning their effects on mortality and morbidity. Specifically, individuals with 572 severe conditions like stroke or multiple chronic diseases may exhibit higher SMR and lower qCM val-573 ues. Similarly, immunocompromised individuals often have additional comorbidities, suggesting that 574 a lower qCM threshold could also be considered for this group. However, making slight adjustments 575 to these parameters is unlikely to significantly alter the model outcomes. 576





Fig. 5: Health episode costs and QALY losses (together with uncertainties) used in the health economic assessment. All data is from the PANORAMIC (Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 in the Community) trial [28]dataset of 2484 individuals with symptoms consistent with COVID-19. We estimated the healthcare costs per day from the raw data using a generalised linear model (GLM) with log-link. We estimated the hospitalisation and ICU QALY losses using beta regression. We estimated the QALY loss from premature death using risk-group specific increases in mortality and lower quality of life estimates [31] and a discounting of 3.5% per year. We colour code all the estimated values by risk group status: no-risk (green, left of each triplet group); at-risk but not immunosuppressed (purple, centre of each triplet group); and immunosuppressed (orange, right of each triplet group); fainter box-whisker plots are for age/risk-groups where there were no data and displayed results are extrapolations.

#### 4.4 **Public and Patient Involvement**

As part of the MEMVIE programme of research, which seeks to embed public and patient voices within 580 vaccination modelling studies [35], we presented the models from this study to a standing group of six 581 public contributors. We presented the model methodology and findings in an accessible narrative form 582 by the modelling team, allowing the PPI group to question the assumptions, parameters and findings. 583 Due to time constraints on the modelling team, in this instance the discussion took place after (rather 584 than during) model development; however, the PPI discussions form part of ongoing work to further 585 refine the MEMVIE Framework for Public Involvement in Mathematical and Economic Modelling, 586 and to facilitate PPI implementation within vaccination modelling. 587

# Author contributions

Matt J. Keeling: Conceptualisation, Formal analysis, Funding acquisition, Methodology, Software, Validation, Visualisation, Writing - Original Draft, Writing - Review & Editing.	589 590
<b>Edward M. Hill:</b> Funding acquisition, Methodology, Visualisation, Writing - Original Draft, Writing - Review & Editing.	591 592
Stavros Petrou: Funding acquisition, Methodology, Writing - Review & Editing.	593
Phuong Bich Tran: Data curation, Formal analysis, Methodology, Writing - Review & Edit-	594 595
May Ee Png: Data curation, Formal analysis, Methodology, Writing - Review & Editing.	596
Sophie Staniszewska: Funding acquisition, Investigation, Writing - Review & Editing.	597
Corinna Clark: Funding acquisition, Investigation, Writing - Review & Editing.	598
Katie Hassel: Data curation, Investigation, Resources, Writing - Review & Editing.	599
Julia Stowe: Data curation, Investigation, Resources, Writing - Review & Editing.	600
Nick Andrews: Data curation, Investigation, Resources, Writing - Review & Editing.	601

# Financial disclosure

This research (MJK, EMH, SP, PT, SS and CC) is funded by the National Institute for Health 603 and Care Research (NIHR) Policy Research Programme (MEMVIE 3, NIHR204667). In addition: 604 MJK was supported by the Engineering and Physical Sciences Research Council through the MathSys 605 CDT [grant number EP/S022244/1] and by the Medical Research Council through the JUNIPER 606 partnership award [grant number MR/X018598/1]. SP receives support as an NIHR senior investigator 607 (NF-SI-0616-10103) and from the UK NIHR Applied Research Collaboration Oxford and Thames 608 Valley. The PANORAMIC study was funded by the NIHR (NIHR135366). EMH is affiliated to the 609 National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in 610 Gastrointestinal Infections at University of Liverpool (PB-PG-NIHR-200910), in partnership with the 611 UK Health Security Agency (UKHSA), in collaboration with the University of Warwick. EMH was 612 funded by The Pandemic Institute, formed of seven founding partners: The University of Liverpool, 613 Liverpool School of Tropical Medicine, Liverpool John Moores University, Liverpool City Council, 614 Liverpool City Region Combined Authority, Liverpool University Hospital Foundation Trust, and 615 Knowledge Quarter Liverpool (EMH is based at The University of Liverpool). The views expressed 616 are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social 617 Care, the UK Health Security Agency or The Pandemic Institute. 618

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

# Data availability

The raw study data are protected and are not available due to data privacy laws. This work is carried out under Regulation 3 of The Health Service (Control of Patient Information) (Secretary of State for Health, 2002) (3) using patient identification information without individual patient consent. Data 626

623

588

cannot be made publicly available for ethical and legal reasons, i.e. public availability would compromise patient confidentiality as data tables list single counts of individuals rather than aggregated data.

### Governance

630

634

638

639

UKHSA has legal permission, provided by Regulation 3 of The Health Service (Control of Patient <sup>631</sup> Information) Regulations 2002, to process patient confidential information for national surveillance of <sup>632</sup> communicable diseases and as such, individual patient consent is not required. <sup>633</sup>

# Ethical approvals

The UK Medicines and Healthcare products Regulatory Agency and the South Central - Berkshire Research Ethics Committee of the Health Research Authority approved the PANORAMIC trial (reference: 21/SC/0393).

# **Competing interests**

All authors declare that they have no competing interests.

## References

- [1] Office National Statistics. Coronavirus (COVID-19)for latest insights: In-Total people infected (2023).URL https://www.ons.gov.uk/ fections peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/ coronaviruscovid19latestinsights/infections#total-people-infected. [Online] (Accessed: 08 November 2024).
- [2] Office for National Statistics. Coronavirus (COVID-19) latest insights: Vaccines (2023). URL https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/ conditionsanddiseases/articles/coronaviruscovid19latestinsights/vaccines. [Online] (Accessed: 08 November 2024).
- [3] NHS England. Vaccinations: COVID-19 (2024). URL https://www.england.nhs.uk/ statistics/statistical-work-areas/covid-19-vaccinations/. [Online] (Accessed: 08 November 2024).
- [4] Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. *PLoS computational biology* 17(5):e1008849 (2021). doi:10.1371/ journal.pcbi.1008849.
- [5] Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. *Lancet Infect. Dis.* 21(6):793–802 (2021). doi:10.1016/S1473-3099(21)00143-2.
- [6] Hill EM, Keeling MJ. Comparison between one and two dose SARS-CoV-2 vaccine prioritization for a fixed number of vaccine doses. *Journal of the Royal Society Interface* 18(182):20210214 (2021). doi:10.1098/rsif.2021.0214.
- [7] UK Health Security Agency. COVID-19 vaccine surveillance report: 18 July 2024 (week 29) (2024). URL https://assets.publishing.service.gov.uk/media/669923b20808eaf43b50d1fd/Vaccine\_surveillance\_report\_2024\_week\_29.pdf. [Online] (Accessed: 08 November 2024).
- [8] Zeevat F, van der Pol S, Westra T, Beck E, Postma MJ, et al. Cost-effectiveness analysis of COVID-19 mRNA XBB. 1.5 Fall 2023 vaccination in the Netherlands. medRxiv page 2024.09.26.24314420 (2024). doi:10.1101/2024.09.26.24314420.
- [9] NHS Digital. Secondary Uses Service (2024). URL https://digital.nhs.uk/services/ secondary-uses-service-sus. [Online] (Accessed: 08 November 2024).
- [10] Office for National Satistics. Deaths broken down by age, sex, area and cause of death. (2024). URL https://www.ons.gov.uk/peoplepopulationandcommunity/ birthsdeathsandmarriages/deaths. [Online] (Accessed: 08 November 2024).
- [11] Tessier E, Edelstein M, Tsang C, Kirsebom F, Gower C, et al. Monitoring the covid-19 immunisation programme through a national immunisation management system – england's experience. *International Journal of Medical Informatics* 170:104974 (2023). doi:https://doi.org/10.1016/j. ijmedinf.2022.104974.
- [12] JCVI. Code of Practice: Joint Committee on Vaccination and Immunisation; 2013 (2013). URL https://assets.publishing.service.gov.uk/government/uploads/system/uploads/ attachment\_data/file/224864/JCVI\_Code\_of\_Practice\_revision\_2013\_-\_final.pdf. [Online] (Accessed: 08 November 2024).

- [13] Public Health Scotland. Viral Respiratory Diseases (including Influenza and COVID-19) in Scotland Surveillance Report (2024). URL https://publichealthscotland.scot/media/29604/ week-41-17-10-24-viral-respiratory-diseases-including-influenza-and-covid-19-in-scotlandpdf.
- [14] Kirsebom FC, Stowe J, Bernal JL, Allen A, Andrews N. Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study. *Journal of Infection* 89(1):106177 (2024).
- [15] Feikin DR, Higdon MM, Andrews N, Collie S, Knoll MD, et al. Assessing covid-19 vaccine effectiveness against omicron subvariants: Report from a meeting of the world health organization. *Vaccine* 41(14):2329–2338 (2023).
- [16] Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Bernal JL. Duration of protection of ancestralstrain monovalent vaccines and effectiveness of bivalent ba. 1 boosters against covid-19 hospitalisation in england: a test-negative case-control study. *The Lancet Infectious Diseases* 23(11):1235– 1243 (2023).
- [17] Kirsebom FCM, Harman K, Lunt RJ, Andrews N, Groves N, et al. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ. 1, CH. 1.1. and XBB. 1.5 in England. The Lancet Regional Health–Europe 35 (2023).
- [18] Davies NG, Klepac P, Liu Y, Prem K, Jit M, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat. Med. 26(8):1205–1211 (2020). doi:10.1038/ s41591-020-0962-9.
- [19] Keeling MJ, Hill EM, Gorsich EE, Penman B, Guyver-Fletcher G, et al. Predictions of COVID-19 dynamics in the UK: Short-term forecasting and analysis of potential exit strategies. PLOS Comput. Biol. 17(1):e1008619 (2021). doi:10.1371/journal.pcbi.1008619.
- COVID-19 vaccinations, [20] JCVI. JCVI on spring 2023Februstatement 222023 (2023).ary URL https://www.gov.uk/government/publications/ spring-2023-covid-19-vaccination-programme-jcvi-advice-22-february-2023/ jcvi-statement-on-spring-2023-covid-19-vaccinations-22-february-2023. [Online] (Accessed: 08 November 2024).
- [21] JCVI. JCVI statement on the COVID-19 vaccination programme for autumn 2023, 26 May 2023 (2023). URL https://www.gov.uk/government/publications/ covid-19-autumn-2023-vaccination-programme-jcvi-advice-26-may-2023/ jcvi-statement-on-the-covid-19-vaccination-programme-for-autumn-2023-26-may-2023. [Online] (Accessed: 08 November 2024).
- [22] UK Health Security Agency (Eds Ramsay, Mary). Immunisation against infectious diseases, Chapter 14a. The Stationery Office (2024).
- [23] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584(7821):430–436 (2020).
- [24] Kohli MA, Maschio M, Joshi K, Lee A, Fust K, et al. The potential clinical impact and costeffectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. Journal of Medical Economics 26(1):1532–1545 (2023). doi:10.1080/13696998.2023.2281083.

- [25] Mahasing C, Suphanchaimat R, Teekasap P, Nittayasoot N, Wongsanuphat S, et al. Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023. Plos one 19(9):e0310427 (2024). doi:10.1371/journal.pone.0310427.
- [26] NHS Digital. Cohorting as a Service. (2024). URL https://digital.nhs.uk/services/ cohorting-as-a-service-caas. [Online] (Accessed: 08 November 2024).
- [27] Keeling MJ, Dyson L. A retrospective assessment of forecasting the peak of the sars-cov-2 omicron ba. 1 wave in england. PLOS Computational Biology 20(9):e1012452 (2024).
- [28] University of Oxford. Homepage PANORAMIC trial (2022). URL https://www.panoramictrial.org/homepage. [Online] (Accessed: 08 November 2024).
- [29] NHS England. 2022/23 National Cost Collection Data Publication (2024). URL https://www. england.nhs.uk/publication/2022-23-national-cost-collection-data-publication/. [Online] (Accessed: 08 November 2024).
- [30] Png ME, Harris V, Grabey J, Hart ND, Jani BD, et al. Cost-utility analysis of molnupiravir for high-risk, community-based adults with covid-19: an economic evaluation of the panoramic trial. British Journal of General Practice 74(745):e570–e579 (2024). doi:https://doi.org/10.3399/ BJGP.2023.0444.
- [31] Briggs AH, Goldstein DA, Kirwin E, Meacock R, Pandya A, et al. Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. Health Economics 30(3):699–707 (2021).
- [32] Jia H, Zack MM, Thompson WW. The effects of diabetes, hypertension, asthma, heart disease, and stroke on quality-adjusted life expectancy. Value in Health 16(1):140–147 (2013).
- [33] Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Medicine 20(1):e1004086 (2023).
- [34] Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. *Patient* preference and adherence pages 621–629 (2014).
- [35] Staniszewska S, Hill EM, Grant R, Grove P, Porter J, et al. Developing a framework for public involvement in mathematical and economic modelling: bringing new dynamism to vaccination policy recommendations. The Patient-Patient-Centered Outcomes Research 14:435–445 (2021). doi:10.1007/s40271-020-00476-x.

Supplementary Tables

and values less than £1 are indicated. Ages, risk-groups and estimates where the willingness to pay threshold is determined by the JCVI uncertainty 

 Table 3: Willingness to pay thresholds for the Spring 2023 boosters.
 Thresholds are given for all ages (although ages 15-39 have been amalgamated

 for simplicity), for no-risk, at-risk and universal vaccine deployment and for the five estimates of vaccine efficacy. Values are rounded to the nearest pound, condition (that there is a 90% chance of cost-effectiveness at  $\pounds 30,000$  per QALY) are marked with an asterisk. Shaded cells correspond with ages and risk groups where vaccination was recommended in the Spring 2023 COVID-19 vaccination programme [20].

			Jniversal					No Risk				7	At Risk		
Age	E1	E2a	E2b	E3a	E3b	E1	E2a	E2b	E3a	E3b	E1	E2a	E2b	E3a	E3b
5-39	ı	< £1 *	< £1 *	£1	< £1	1	< £1 *	< £1 *	< £1	< £1	< £1	£1 *	£1 *	$\leq \pounds 2$	£1
0-44	ı	< £1	$< \pounds 1^{*}$	$\mathfrak{L}1$	< £1	1	< £1	< £1 *	$< \pounds 1$	$< \pounds 1$	$< \mathfrak{L}1$	$\mathfrak{L}1$	£1	$\mathfrak{L3}$	£1
5-49	,	£1	< £1	£1	£1		< £1 *	< £1 *	£1	< £1 *	< £1	f2	£1	$\mathfrak{L}5$	$\pounds2$
0-54	1	£1	£1	f2	£1		< £1	< £1	£1	< £1	< £1	£3	f2	£7	$\mathfrak{L}4$
5-59	1	f2	£1	£3	f2	1	£1	£1	£1	< £1	£1 *	£4	£3	£8	$\mathfrak{L}4$
0-64	ı	f2	£1	$\mathfrak{L}\mathfrak{L}$	f2	1	£1	£1	$\pounds 2$	£1	$< \mathfrak{L}1$	$\mathfrak{L}4$	f3	$\pounds 10$	$\mathfrak{L}_{5}^{\mathbf{c}}$
5-69	£1 *	${ m f6}$	£4	£11	f6	< £1	$\pounds 2$	£1	$\mathfrak{L3}$	f2	$\pounds2 *$	$\pounds 10$	$\mathfrak{L}7$	$\pounds 20$	£11
0-74	£3 *	£7	$\mathfrak{L}\mathfrak{L}$	$\pounds 16$	£8	£3 *	£3	f2	$\mathfrak{L5}$	f3	£3 *	£11	£7	f26	£13
5-79	£27	$\pounds 16$	£11	$\pounds34$	£17	$\pounds 21$	f8	£7	$\pounds 13$	£7	f32	$\pounds 20$	$\pounds 13$	£48	$\pounds 23$
0-84	£33	f20	£13	$\pounds 50$	$\pounds 24$	f25	£11	$\pounds 10$	$\pounds 20$	$f_{0}$	f36	$\pounds24$	$\pounds 15$	f62	f30
5-89	$\pounds 36$	f38	$\pounds 26$	$\pounds92$	f44	£15 *	£27	£24 *	£48	$\pounds24$	f39	$\pounds41$	f26	$\pounds103$	f50
+06	£19 *	£36	f22	$\pounds 101$	£47	< £1	$\pounds 31$	$\pounds 27$	f53	$\pounds 27$	f35	$\pounds37$	$\pounds 21$	£111	$\pounds 51$

boosters. Thresholds are given for all ages, for no-risk, at-risk and universal vaccine	unded to the nearest pound, and values less than $\pounds 1$ are indicated. Ages, risk-groups	the JCVI uncertainty condition (that there is a 90% chance of cost-effectiveness at	ond with ages and risk groups where vaccination was recommended in the Autumn	
Table 4: Willingness to pay thresholds for the Autumn 20	deployment and for the five estimates of vaccine efficacy. Values are	and estimates where the willingness to pay threshold is determined	£30,000 per QALY) are marked with an asterisk. Shaded cells cor	2023 COVID-19 vaccination programme [21].

			Universal					No Risk				T	At Risk		
Age	E1	E2a	E2b	E3a	E3b	E1	E2a	E2b	E3a	E3b	E1	E2a	E2b	E3a	E3b
15-19	,	< £1	< £1	< £1	< £1	ı	< £1	< £1	$< \pounds 1$	< £1	< £1	£2 *	£2 *	$\mathfrak{f}3$	£2 *
20-24	1	< £1	< £1 *	< £1	< £1	1	< £1	< £1 *	< £1	< £1	< £1	£1 *	£1 *	£2 *	£1 *
25-29	1	< £1 *	< £1 *	£1 *	< £1 *	1	< £1 *	< £1 *	< £1 *	< £1 *	< £1	£1 *	£1 *	£2 *	£1 *
30-34	1	£1	< £1	£1	< £1	1	< £1	< £1	< £1	< £1	< £1	$\pounds 2$	$\mathfrak{L}1$	f3	£1
35-39	1	£1 *	£1 *	£1 *	£1 *	1	$< \pounds 1^{*}$	< £1 *	< £1 *	< £1 *	< f1	$\pounds 2$	f2	$\mathfrak{L}4$	$\pounds 2$
40-44	,	£1	£1	£1	£1	1	< £1	< £1	< £1	< £1	< £1	$\mathfrak{L}\mathfrak{L}$	$\mathfrak{L}4$	£7	$\pounds 4$
45-49	,	$\pounds 2$	£1	f2	£1	1	£1	£1	£1	£1	< £1	$\mathfrak{L}\mathfrak{L}$	$\mathfrak{L}4$	£7	f3
50-54	1	£3	£3	£4	$\pounds 2$	1	£1	£1	£1	£1	< £1	f9	f8	$\pounds 13$	$\mathfrak{L7}$
55-59	1	£5	£4	f6	£3	1	£2	£2	£2	£1	< £1	$\pounds 12$	$\pounds 11$	$\pounds 17$	$f_0$
60-64	1	$\mathfrak{L7}$	${ m f6}$	$\pounds 10$	$\mathfrak{L5}$	ı	$\mathfrak{L}3$	$\pounds 2$	f3	f2	£5 *	$\pounds 15$	$\pounds 13$	$\pounds 22$	£11
62-69	$\pounds14$	$\pounds 16$	£14	$\pounds 21$	$\pounds 10$	$\mathfrak{L7}$	$\mathfrak{L}6$	$\mathfrak{L}6$	${ m f6}$	£3	$\pounds24$	$\pounds 29$	$\pounds 25$	$\pounds 41$	$\pounds 19$
70-74	f29	$\pounds24$	f22	£34	$\pounds 15$	£11	$\pounds 10$	$\pounds 10$	$\pounds 10$	£4	$\pounds 45$	f37	$\pounds 33$	$\pounds 57$	f25
75-79	$\pounds74$	£51	£48	£80	f30	$\pounds 41$	f25	$\pounds 27$	$\pounds 25$	$\pounds 10$	f95	$\pounds 67$	$\pounds 62$	£114	f43
80-84	f84	$\pounds72$	f68	$\pounds 128$	$\pounds 45$	f49	$\pounds42$	f45	f43	$\pounds 16$	f98	f83	£77	$\pounds 162$	f57
85-89	$\pounds169$	$\pounds 134$	$\pounds 125$	$\pounds 228$	£83	$\pounds 119$	£89	f95	$\mathfrak{L}94$	$\pounds 36$	$\pounds 182$	$\pounds 146$	$\pounds 133$	$\pounds 263$	f95
+06	£148	£141	£132	$\pounds 275$	£97	£19 *	£97	£99	$\pounds 100$	$\pounds 45$	$\pounds 172$	$\pounds 150$	$\pounds 138$	f309	$\pounds 107$

perpetuity. It is made available under a CC-BY 4.0 International license .

Table 5: Summary of health economic values for hospitalisation, ICU and death events. We provide the following statistics stratified by age-group and risk status, which are displayed in Fig. 5. For infection episodes resulting in hospitalisation and ICU admission, we report the mean estimates (with 95% confidence intervals in parentheses) for the cost per day (£) to the nearest integer and QALY loss to 2 decimal places. Estimates in regular typeface are from the PANORAMIC trial (Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 in the Community) [28], with estimates in italic typeface corresponding to age and risk-groups where there were no data and displayed results are extrapolations. Per death we report the QALY loss to 2 decimal places, with estimates produced using the approach of Briggs *et al.* [31] to adjust for the presence of comorbidities that influence both life-expectancy and health-related quality of life.

		Hospital	isation	IC	U	Death
Age	Risk status	Cost per day (£)	QALY loss	Cost per day (£)	QALY loss	QALY loss
	Not at risk	819 (459,1463)	0.27 (-0.02,0.56)	1739 (1155,2620)	0.47 (-0.84,1.77)	23.61
15-19	At-risk	518(32,8331)	0.24 (- $0.05, 0.52$ )	1574 (897,2762)	0.17 (-0.69, 1.02)	20.89
	Immunosuppressed	409(26,6573)	0.19 (-0.10,0.47)	1629 (1095,2421)	0.38 (-0.43,1.20)	18.31
	Not at risk	819 (459,1463)	0.27 (-0.02, 0.56)	1739 (1155,2620)	0.47 (-0.84,1.77)	21.72
20-24	At-risk	749(421,1334)	0.24 (-0.05, 0.52)	1574 (897,2762)	0.17 (-0.69,1.02)	19.08
	Immunosuppressed	591(330,1060)	0.19(-0.10, 0.47)	1629 (1095,2421)	0.38 (-0.43,1.20)	16.62
	Not at risk	891 (573,1386)	0.30 (-0.01, 0.61)	1739 (1155,2620)	0.47 (-0.84,1.77)	21.72
25 - 29	At-risk	815 (527,1261)	0.28 (-0.03, 0.58)	1574 (897,2762)	0.17 (-0.69, 1.02)	19.08
	Immunosuppressed	643 (411,1008)	0.23 (-0.08, 0.54)	$1629 \ (1095, 2421)$	0.38 (-0.43,1.20)	16.62
	Not at risk	$1223 \ (978, 1530)$	$0.28 \ (0.09, 0.47)$	1739 (1155,2620)	0.47 (-0.84,1.77)	19.52
30-34	At-risk	1119 (900, 1390)	$0.25\ (0.07, 0.44)$	1776(1312,2405)	0.17 (-0.69, 1.02)	16.96
	Immunosuppressed	883 (693,1124)	$0.20\ (0.01, 0.39)$	1629(1095,2421)	0.38 (-0.43,1.20)	14.64
	Not at risk	$1202 \ (942, 1533)$	$0.28 \ (0.08, 0.48)$	$1739\ (1155,2620)$	0.47 (-0.84,1.77)	19.52
35-39	At-risk	$1099 \ (869, 1389)$	$0.25 \ (0.06, 0.45)$	1862 (1348,2571)	0.17 (-0.69,1.02)	16.96
	Immunosuppressed	867 (671,1120)	$0.21 \ (0.01, 0.41)$	1628 (1095, 2421)	0.38 (-0.43,1.20)	14.64
	Not at risk	1203 (987, 1467)	$0.27 \ (0.12, 0.43)$	1739 (1155,2620)	0.47 (-0.84,1.77)	16.73
40-44	At-risk	1100 (913, 1325)	$0.24 \ (0.09, 0.39)$	1951 (1385,2748)	0.17 (-0.69, 1.02)	14.30
	Immunosuppressed	868 (700,1077)	$0.20\ (0.04, 0.35)$	2043 (1433,2912)	0.38 (-0.43,1.20)	12.19
	Not at risk	$1104 \ (895, 1361)$	$0.29\ (0.15, 0.43)$	1739 (1155,2620)	0.47 (-0.84,1.77)	16.73
45-49	At-risk	$1009 \ (828, 1230)$	$0.26\ (0.13, 0.39)$	1607 (916, 2819)	0.28 (-0.49, 1.05)	14.30
	Immunosuppressed	797 (636,998)	$0.21 \ (0.07, 0.36)$	2181 (1530,3109)	0.38 (-0.43,1.20)	12.19
	Not at risk	1249 (1107, 1409)	$0.29 \ (0.20, 0.38)$	1700 (1147,2520)	0.47 (-0.84, 1.77)	13.79
50-54	At-risk	$1142 \ (1005, 1297)$	$0.26 \ (0.16, 0.36)$	2225 (1617, 3062)	0.39 (-0.30, 1.08)	11.52
	Immunosuppressed	901 (758,1072)	0.21 (0.10, 0.33)	$2330\ (1635,3319)$	0.38 (-0.43,1.20)	9.64
	Not at risk	1273(1131,1434)	$0.30\ (0.20, 0.39)$	1661 (1139,2424)	0.47 (-0.84, 1.77)	13.79
55-59	At-risk	$1164 \ (1029, 1317)$	0.27 (0.17, 0.37)	1797 (1340,2409)	0.40 (-0.25, 1.06)	11.52
	Immunosuppressed	919 (776,1089)	0.22(0.11, 0.34)	$1556\ (1057,2289)$	0.47 (-0.68, 1.63)	9.64
	Not at risk	1183 (1039,1347)	0.28(0.19, 0.37)	1621 (1187, 2214)	0.41 (-0.30, 1.11)	10.64
60-64	At-risk	1082 (947, 1236)	0.25(0.16, 0.34)	1450 (1110,1895)	0.42 (-0.20, 1.04)	8.61
	Immunosuppressed	854 (716,1019)	0.20 (0.09,0.32)	1518 (1143,2017)	0.42 (-0.29,1.12)	7.04
	Not at risk	1274 (1117,1452)	0.30(0.20,0.40)	2139(1635,2797)	0.29 (-0.32, 0.91)	10.64
65-69	At-risk	1165 (1017, 1334)	0.27 (0.17, 0.37)	1913 (1531,2390)	0.32 (-0.21, 0.85)	8.61
	Immunosuppressed	919 (769,1098)	0.22 (0.11,0.34)	$\frac{2003 (1574,2548)}{1755 (1945,9474)}$	$\frac{0.32 (-0.24, 0.87)}{0.32 (-0.24, 0.87)}$	7.04
70 74	Not at risk	1413(1240,1609) 1909(1191,1476)	0.29(0.18,0.40)	1755(1245,2474) 1570(1170,2100)	0.36(-0.35,1.07)	7.14
70-74	At-risk	1292 (1131, 1470) 1020 (952, 1210)	0.27 (0.10, 0.37)	1570 (1170,2106) 1642 (1102,2265)	0.38 (-0.24, 1.00)	5.50
	Net et siele	$1020 (803,1219) \\1182 (1011,1281)$	$\begin{array}{c} 0.22 \ (0.09, 0.35) \\ \hline 0.20 \ (0.18 \ 0.42) \end{array}$	$1043 (1192,2203) \\1820 (1411,2207)$	$\frac{0.38 (-0.30, 1.11)}{0.20 (-0.20, 0.87)}$	4.34
75 70	Not at risk	1182 (1011,1381) 1080 (025 1262)	0.30(0.18,0.42) 0.27(0.16,0.20)	1839(1411,2397) 1645(1221,2048)	0.29 (-0.29, 0.87)	(.14
10-19	At-risk	1000 (920, 1202) 852 (701, 1028)	0.27 (0.10, 0.39) 0.22 (0.00, 0.26)	1040 (1521,2046) 1700 (1220,2006)	0.31 (-0.24, 0.61)	3.30
	Not at rials		0.23(0.09,0.30)	$\frac{1122 (1332,2220)}{1820 (1111,0207)}$	0.38(-0.30,1.11)	4.34
00.04	At might	1102 (1011,1301) 1000 (005 1060)	0.30 (0.16, 0.42)	1639(1411,2397) 1615(19010019)	0.29 (-0.29, 0.07)	4.10
00-04	At-risk Immunosuppressed	1000 (925,1202) 859 (701 1098)	0.27 (0.10, 0.39) 0.99 (0.00, 0.96)	1040 (1021,2048)	0.31 (-0.24, 0.01) 0.28 (-0.26, 1, 11)	3.00
	Not at risk		$\frac{0.23 (0.09, 0.30)}{0.20 (0.18 0.10)}$	1830 (1/11 0207)	$\frac{0.00 (-0.00, 1.11)}{0.00 (-0.00 0.087)}$	2.20 A 15
85-80	At-risk		0.00 (0.10,0.42)	1615(12010018)	0.23 (-0.23, 0.01) 0.31 (-0.91, 0.87)	3 00
00-09	Immunosuppressed	853 (701 1098)	0.27 (0.10, 0.09) 0.93 (0.00 0.26)	1799 (1929 9996)	0.31 (-0.24, 0.01) 0.38 (-0.36 + 11)	9.00 9.95
	Not at risk	1189 (1011 1981)	$\frac{0.20 (0.03, 0.00)}{0.30 (0.18 0.10)}$	1839 (1/11 0207)	0.00 (-0.00, 1.11)	2.23
90+	At-risk	1080 (925 1262)	0.27 (0.16, 0.42)	16/5 (1321 20/8)	0.31 (-0.23, 0.87)	1 39
	Immunosuppressed	853 (701 10.98)	0.23 (0.09 0.36)	1722 (1332 2296)	$0.38 (-0.36 \ 1 \ 11)$	1.00
	u	[ 000 (101,1000)	0.00,0.00)	1122 (1002,2220)		1.00